CRISPR-engineered T cells in patients with refractory cancer

被引：1027

作者：

Stadtmauer, Edward A. ^{[1
,2
]}

Fraietta, Joseph A. ^{[2
,3
,4
,5
,6
]}

Davis, Megan M. ^{[5
,6
]}

Cohen, Adam D. ^{[1
,2
]}

Weber, Kristy L. ^{[2
,7
]}

Lancaster, Eric ^{[8
]}

Mangan, Patricia A. ^{[1
]}

Kulikovskaya, Irina ^{[5
]}

Gupta, Minnal ^{[5
]}

Chen, Fang ^{[5
]}

Tian, Lifeng ^{[5
]}

Gonzalez, Vanessa E. ^{[5
]}

Xu, Jun ^{[5
]}

Jung, In-young ^{[4
,5
]}

Melenhorst, J. Joseph ^{[3
,5
,6
]}

Plesa, Gabriela ^{[5
]}

Shea, Joanne ^{[5
]}

Matlawski, Tina ^{[5
]}

Cervini, Amanda ^{[5
]}

Gaymon, Avery L. ^{[5
]}

Desjardins, Stephanie ^{[5
]}

Lamontagne, Anne ^{[5
]}

Salas-Mckee, January ^{[5
]}

Fesnak, Andrew ^{[5
,6
]}

Siegel, Donald L. ^{[5
,6
]}

Levine, Bruce L. ^{[5
,6
]}

Jadlowsky, Julie K. ^{[5
]}

Young, Regina M. ^{[5
]}

Chew, Anne ^{[5
]}

Hwang, Wei-Ting ^{[9
]}

Hexner, Elizabeth O. ^{[1
,2
]}

Carreno, Beatriz M. ^{[3
,5
,6
]}

Nobles, Christopher L. ^{[4
]}

Bushman, Frederic D. ^{[4
]}

Parker, Kevin R. ^{[10
]}

Qi, Yanyan ^{[11
]}

Satpathy, Ansuman T. ^{[10
,11
]}

Chang, Howard Y. ^{[10
,12
]}

Zhao, Yangbing ^{[5
,6
]}

Lacey, Simon F. ^{[5
,6
]}

June, Carl H. ^{[2
,3
,5
,6
]}

机构：

[1] Univ Penn, Dept Med, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Univ Penn, Parker Inst Canc Immunotherapy, Perelman Sch Med, Philadelphia, PA 19104 USA

[4] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA

[5] Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA

[6] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA

[7] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA

[8] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA

[9] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA

[10] Stanford Univ, Sch Med, Ctr Personal Dynam Regulomes, Stanford, CA 94305 USA

[11] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA

[12] Stanford Univ, Howard Hughes Med Inst, Sch Med, Stanford, CA 94305 USA

来源：

SCIENCE | 2020年 / 367卷 / 6481期

基金：

美国国家卫生研究院;

关键词：

DOUBLE-STRAND BREAKS; LYMPHOCYTES; PD-1; GENOME; PERSISTENCE; NY-ESO-1; INDUCTION; RECOGNIZE; LEUKEMIA; AFFINITY;

D O I：

10.1126/science.aba7365

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

CRISPR-Cas9 gene editing provides a powerful tool to enhance the natural ability of human T cells to fight cancer. We report a first-in-human phase 1 clinical trial to test the safety and feasibility of multiplex CRISPR-Cas9 editing to engineer T cells in three patients with refractory cancer. Two genes encoding the endogenous T cell receptor (TCR) chains, TCR alpha (TRAC) and TCR beta (TRBC), were deleted in T cells to reduce TCR mispairing and to enhance the expression of a synthetic, cancer-specific TCR transgene (NY-ESO-1). Removal of a third gene encoding programmed cell death protein 1 (PD-1; PDCD1), was performed to improve antitumor immunity. Adoptive transfer of engineered T cells into patients resulted in durable engraftment with edits at all three genomic loci. Although chromosomal translocations were detected, the frequency decreased over time. Modified T cells persisted for up to 9 months, suggesting that immunogenicity is minimal under these conditions and demonstrating the feasibility of CRISPR gene editing for cancer immunotherapy.

引用

页码：1001 / +

页数：79

共 55 条

[41] Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State [J].

Schietinger, Andrea ;

Delrow, Jeffrey J. ;

Basom, Ryan S. ;

Blattman, Joseph N. ;

Greenberg, Philip D. .

SCIENCE, 2012, 335 (6069) :723-727

[42] Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function [J].

Schober, Kilian ;

Mueller, Thomas R. ;

Goekmen, Fuesun ;

Grassmann, Simon ;

Effenberger, Manuel ;

Poltorak, Mateusz ;

Stemberger, Christian ;

Schumann, Kathrin ;

Roth, Theodore L. ;

Marson, Alexander ;

Busch, Dirk H. .

NATURE BIOMEDICAL ENGINEERING, 2019, 3 (12) :974-984

[43] Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade [J].

Serganova, Inna ;

Moroz, Ekaterina ;

Cohen, Ivan ;

Moroz, Maxim ;

Mane, Mayuresh ;

Zurita, Juan ;

Shenker, Larissa ;

Ponomarev, Vladimir ;

Blasberg, Ronald .

MOLECULAR THERAPY-ONCOLYTICS, 2017, 4 :41-54

[44] Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population [J].

Simhadri, Vijaya L. ;

McGill, Joseph ;

McMahon, Shane ;

Wang, Junxia ;

Jiang, Haiyan ;

Sauna, Zuben E. .

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2018, 10 :105-112

[45] CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients [J].

Su, Shu ;

Hu, Bian ;

Shao, Jie ;

Shen, Bin ;

Du, Juan ;

Du, Yinan ;

Zhou, Jiankui ;

Yu, Lixia ;

Zhang, Lianru ;

Chen, Fangjun ;

Sha, Huizi ;

Cheng, Lei ;

Meng, Fanyan ;

Zou, Zhengyun ;

Huang, Xingxu ;

Liu, Baorui .

SCIENTIFIC REPORTS, 2016, 6

[46] Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia [J].

Teachey, David T. ;

Lacey, Simon F. ;

Shaw, Pamela A. ;

Melenhorst, J. Joseph ;

Maude, Shannon L. ;

Frey, Noelle ;

Pequignot, Edward ;

Gonzalez, Vanessa E. ;

Chen, Fang ;

Finklestein, Jeffrey ;

Barrett, David M. ;

Weiss, Scott L. ;

Fitzgerald, Julie C. ;

Berg, Robert A. ;

Aplenc, Richard ;

Callahan, Colleen ;

Rheingold, Susan R. ;

Zheng, Zhaohui ;

Rose-John, Stefan ;

White, Jason C. ;

Nazimuddin, Farzana ;

Wertheim, Gerald ;

Levine, Bruce L. ;

June, Carl H. ;

Porter, David L. ;

Grupp, Stephan A. .

CANCER DISCOVERY, 2016, 6 (06) :664-679

[47] Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV [J].

Tebas, Pablo ;

Stein, David ;

Tang, Winson W. ;

Frank, Ian ;

Wang, Shelley Q. ;

Lee, Gary ;

Spratt, S. Kaye ;

Surosky, Richard T. ;

Giedlin, Martin A. ;

Nichol, Geoff ;

Holmes, Michael C. ;

Gregory, Philip D. ;

Ando, Dale G. ;

Kalos, Michael ;

Collman, Ronald G. ;

Binder-Scholl, Gwendolyn ;

Plesa, Gabriela ;

Hwang, Wei-Ting ;

Levine, Bruce L. ;

June, Carl H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (10) :901-910

[48] GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases [J].

Tsai, Shengdar Q. ;

Zheng, Zongli ;

Nguyen, Nhu T. ;

Liebers, Matthew ;

Topkar, Ved V. ;

Thapar, Vishal ;

Wyvekens, Nicolas ;

Khayter, Cyd ;

Iafrate, A. John ;

Le, Long P. ;

Aryee, Martin J. ;

Joung, J. Keith .

NATURE BIOTECHNOLOGY, 2015, 33 (02) :187-197

[49] A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells [J].

Vakulskas, Christopher A. ;

Dever, Daniel P. ;

Rettig, Garrett R. ;

Turk, Rolf ;

Jacobi, Ashley M. ;

Collingwood, Michael A. ;

Bode, Nicole M. ;

McNeill, Matthew S. ;

Yan, Shuqi ;

Camarena, Joab ;

Lee, Ciaran M. ;

Parka, So Hyun ;

Wiebking, Volker ;

Bak, Rasmus O. ;

Gomez-Ospina, Natalia ;

Pavel-Dinu, Mara ;

Sun, Wenchao ;

Bao, Gang ;

Porteus, Matthew H. ;

Behlke, Mark A. .

NATURE MEDICINE, 2018, 24 (08) :1216-+

[50] Endogenous DNA double-strand breaks: Production, fidelity of repair, and induction of cancer [J].

Vilenchik, MM ;

Knudson, AG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (22) :12871-12876

← 1 2 3 4 5 6 →